CALIFORNIA NANOTECHNOLOGIES (CNO.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:CNO - CA1304921010 - Common Stock
0.32 CAD
+0.01 (+3.23%)
We assign a fundamental rating of 3 out of 10 to CNO. CNO was compared to 21 industry peers in the Machinery industry. The financial health of CNO is average, but there are quite some concerns on its profitability. CNO is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CNO has reported negative net income.
In the past year CNO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CNO reported negative net income in multiple years.
Each year in the past 5 years CNO had a positive operating cash flow.
1.2 Ratios
The Return On Assets of CNO (-21.51%) is worse than 66.67% of its industry peers.
The Return On Equity of CNO (-39.65%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROIC | N/A |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of CNO has grown nicely.
The Gross Margin of CNO (69.19%) is better than 95.24% of its industry peers.
CNO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CNO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% |
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
2. Health
2.1 Basic Checks
CNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CNO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CNO has been increased compared to 5 years ago.
CNO has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.59 indicates that CNO is not a great score, but indicates only limited risk for bankruptcy at the moment.
CNO has a Altman-Z score of 2.59. This is in the better half of the industry: CNO outperforms 66.67% of its industry peers.
CNO has a debt to FCF ratio of 4.46. This is a neutral value as CNO would need 4.46 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4.46, CNO is doing good in the industry, outperforming 76.19% of the companies in the same industry.
A Debt/Equity ratio of 0.49 indicates that CNO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.49, CNO perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Altman-Z | 2.59 |
ROIC/WACCN/A
WACC9.51%
2.3 Liquidity
A Current Ratio of 1.19 indicates that CNO should not have too much problems paying its short term obligations.
CNO has a Current ratio of 1.19. This is in the lower half of the industry: CNO underperforms 76.19% of its industry peers.
A Quick Ratio of 1.19 indicates that CNO should not have too much problems paying its short term obligations.
CNO has a Quick ratio of 1.19. This is in the better half of the industry: CNO outperforms 76.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
CNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -477.78%.
CNO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.79%.
CNO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 49.59% yearly.
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
3.2 Future
Based on estimates for the next years, CNO will show a very strong growth in Earnings Per Share. The EPS will grow by 103.31% on average per year.
CNO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.35% yearly.
EPS Next Y100%
EPS Next 2Y103.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-41.22%
Revenue Next 2Y-10.35%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CNO. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 22.52, CNO is valued on the expensive side.
CNO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CNO is cheaper than 61.90% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.83. CNO is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.52 |
4.2 Price Multiples
CNO's Enterprise Value to EBITDA ratio is in line with the industry average.
CNO's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CNO is cheaper than 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.34 | ||
| EV/EBITDA | 105.35 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CNO's earnings are expected to grow with 103.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.31%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CNO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:CNO (12/19/2025, 7:00:00 PM)
0.32
+0.01 (+3.23%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.73%
Ins Owner ChangeN/A
Market Cap16.03M
Revenue(TTM)4.45M
Net Income(TTM)-939.70K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.52 | ||
| P/S | 2.61 | ||
| P/FCF | 35.34 | ||
| P/OCF | 5.57 | ||
| P/B | 4.9 | ||
| P/tB | 4.91 | ||
| EV/EBITDA | 105.35 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY4.44%
FCF(TTM)0.01
FCFY2.83%
OCF(TTM)0.06
OCFY17.96%
SpS0.12
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | -39.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% | ||
| FCFM | 7.39% |
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)19.86%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 4.46 | ||
| Debt/EBITDA | 9.55 | ||
| Cap/Depr | 253.96% | ||
| Cap/Sales | 39.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1711.31% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.59 |
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)145.85%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-477.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.82%
EPS Next Y100%
EPS Next 2Y103.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.79%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-48.76%
Revenue Next Year-41.22%
Revenue Next 2Y-10.35%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.85%
EBIT growth 3Y87.4%
EBIT growth 5Y154.28%
EBIT Next Year-67.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.62%
FCF growth 3Y80.29%
FCF growth 5Y42.36%
OCF growth 1Y667.86%
OCF growth 3Y173%
OCF growth 5Y84.63%
CALIFORNIA NANOTECHNOLOGIES / CNO.CA FAQ
What is the ChartMill fundamental rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CNO.CA.
Can you provide the valuation status for CALIFORNIA NANOTECHNOLOGIES?
ChartMill assigns a valuation rating of 4 / 10 to CALIFORNIA NANOTECHNOLOGIES (CNO.CA). This can be considered as Fairly Valued.
How profitable is CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
CALIFORNIA NANOTECHNOLOGIES (CNO.CA) has a profitability rating of 3 / 10.
What is the financial health of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?
The financial health rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) is 4 / 10.